Observational Study to Evaluate Long-Term Outcome in Hip Arthroplasty
Launched by CORIN · Sep 2, 2014
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is an observational study looking at the long-term outcomes of hip replacement surgeries using specific hip devices made by Corin. The goal is to gather important information about how safe and effective these devices are for patients over time. If you or a family member are considering hip replacement surgery, this study could provide valuable insights into what to expect in the years following the procedure.
To participate, individuals must be at least 18 years old and have been advised to undergo hip replacement surgery using Corin devices. However, people with certain health conditions, such as serious tumors or high surgical risks, may not be eligible. Participants in this study will be asked to agree to take part and will need to follow up on their health after surgery. This study is currently recruiting participants of all genders, and it's designed to help improve future hip replacement surgeries for everyone.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Man or woman \>18 years
- • Subjects with indication of arthroplasty surgery with Corin hip devices which are under assessment as part of this PMCF study
- • Subjects who agreed for study participation.
- Exclusion Criteria:
- • Subjects with existing tumour and/or particularly high surgical risk-
- • Subjects with anaesthetic risk class IV or higher
- • Subjects under guardianship and/or unable to follow procedures or matters related to the study (examples: Illiterate, recent psychotic or mania disorders and / or inability to comply with usual follow-up visits.)
- • Contraindications for arthroplasty with a Corin hip devices as per product IFU
About Corin
Corin is a leading medical technology company specializing in the development of innovative solutions for the management of cardiovascular diseases. With a strong focus on improving patient outcomes, Corin leverages advanced data analytics and cutting-edge technology to enhance the precision and effectiveness of cardiac care. The company's commitment to research and development drives its clinical trials, aimed at validating and optimizing its products, ensuring they meet the highest standards of safety and efficacy. Through collaboration with healthcare professionals and institutions, Corin strives to advance the field of cardiology and provide healthcare providers with the tools they need to deliver exceptional patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nice, , France
Dunkerque, , France
Bordeaux, , France
Cannes, , France
Hénin Beaumont, , France
Orléans, , France
Paris, , France
Paris, , France
Pessac, , France
Roubaix, , France
St Georges De Didonne, , France
Toulouse, , France
Valenciennes, , France
Patients applied
Trial Officials
Goulven Rochcongar, MD
Study Chair
University Hospital, Caen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials